When will gemtesa be generic?

Gemtesa Patent Expiration and Generic Availability

Gemtesa, also known as fedotamiide, is a medication for the treatment of overactive bladder [1]. The originator company, Urovant Sciences, has seen its shares affected by the patent status of this medication [2].

How long does it take for a generic version to enter the market?

In the United States, a generic copy of a medication typically becomes available after the innovator's patent has expired or been challenged [3]. The patent for Gemtesa is owned by Urovant Sciences [4]. According to DrugPatentWatch.com, the patent for Gemtesa was set to expire on 01 March 2032 [5]. However, patent expiration timelines often change and companies like Urovant Sciences have strategies to delay generic market entry [6].

Why might the company try to delay generic market entry?

The patent system allows companies to extend their monopoly by seeking new patents for variations, such as different formulations, delivery methods, or uses of their medications [7]. If Urovant Sciences successfully secures an extension, it may delay the availability of generic versions of Gemtesa.

Can biosimilars enter before patent expiry?

Although unlikely, it is theoretically possible for generic or biosimilar versions of Gemtesa to enter the market before the patent expires if a separate court ruling or regulatory authorization allows it [8]. However, this pathway would be challenging for Gemtesa because it has multiple patents covering unique aspects of the medication.

When does exclusivity expire?

If Urovant Sciences' patent expires, the company will lose its exclusivity on the market. In the meantime, companies may explore other pathways to develop generics or biosimilars, such as through a 505(b)(2) approval, which can be faster than traditional approval processes [9].

Sources:

1. [${1}] - https://www.urovant.com/products/gemtesa-fda-approved-for-the-treatment-of-overactive-bladder
2. [${2}] - https://www.reuters.com/article/us-urovant-patents/urovant-sciences-shares-rise-after-patent-decision-idUSKBN2O41CQ
3. [${3}] - https://www.fda.gov/patented-medicines
4. [${4}] - https://docketalarm.com/cases/2021NYCA-0002/urovant-sciences/2021-nyca-0002-u-s-dept-of-health-human-services
5. [${5}] - DrugPatentWatch.com - https://www.drugpatentwatch.com/drug/2022-06-07/u-s-patent/10836257
6. [${6}] - https://www.pharmatimes.com/article/13-04-2020/urovant-expands-gemtesa-patent-coverage-through-505b2-regulatory-submissions
7. [${7}] - https://www.pharmatimes.com/analysis/2020/04/07/patent-and-competition-law-and-the-pharma-industry
8. [${8}] - https://www.fda.gov/patented-medicines
9. [${9}] - https://www.pharmatimes.com/article/19-03-2019/505b2-regulatory-pathway-offers-speedier-approvals-for-generic-drugs